Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo, Shionogi Rush Alternatives To Resistant Flu Strain

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers Daiichi Sankyo, Shionogi and Toyama Chemical are rushing to get anti-flu drugs ready for the market before an outbreak of influenza resistant to the main treatment available. Daiichi Sankyo is stepping up work on its one-dose drug inhaled in powder form and has tested it successfully in animals against the flu strain resistant to Roche's Tamiflu (oseltamivir). The company expects to seek approval by the end of this year. Shionogi has a flu drug in Phase III trials in Japan and South Korea and could file by the end of the year while Toyama expects to finish its version next year. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel